Press Releases

Generian Pharmaceuticals, Inc., a preclinical biopharmaceutical company discovering and developing first-in-class orally bioavailable small molecule therapeutics, announced today that it has achieved the first research milestones for two programs in development under its collaboration agreement with Mitobridge, Inc. (a wholly-owned subsidiary of Astellas Pharma Inc.). The two programs that Generian is advancing are focused on the stabilization or degradation of two unrelated transcr

Signant Health, the leader in evidence generation for modern clinical trials, announced today the ability to deliver computerized adaptive testss in clinical trials utilizing the Patient-Reported Outcome Measure Information System, designed to reduce patient completion burden while maintaining measurement precision of patient-reported outcomes. The new digital health measures, developed by the National Institutes of Health, take advantage of an emerging model of assessment administr

Avicanna Inc. a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that it has entered into a new sub-license agreement with VB Brands California LLC and Player Holdings LLC to exclusively commercialize its Viola-branded products in the United Kingdom territory  where the company has entered into a sub-licensing agreement with Vertical Pharma Resources Limited T/A IPS Pharma  fo

Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announced that the US Food and Drug Administration has accepted its Biologics License Application for proposed biosimilar denosumab. The application includes all indications covered by the reference medicines Prolia (denosumab)* and Xgeva (denosumab)* for treating a variety of conditions, including osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment-induced bone loss

 Azenta, Inc. today announced that it has acquired Ziath, Ltd. and its subsidiaries. Based in Cambridge, UK, Ziath is a leading provider of 2D barcode readers for life sciences applications. Founded in 2005, Ziath's innovative 2D barcode readers are a key component of the laboratory automation workflow serving pharmaceutical, biotech and academic customers worldwide. "As part of Azenta, Ziath will enhance offerings which support the entire lifecycle of the sample –

LivaNova PLC, a market-leading medical technology and innovation company, today launched SenTiva DUO an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy for the treatment of drug-resistant epilepsy. The dual-pin header distinguishes this latest IPG from the original SenTiva which is only available in a single-pin format. Now, with SenTiva DUO, patients considered “the pioneers of VNS Therapy” who were originally implanted with a dual-pin lead and IPG

Amid a continuing supply chain crisis in the U.S. baby formula market, Australian health and wellness company, Care A2 Plus Pty Ltd and American Pharmaceutical Company, Gensco Pharma, have announced a partnership to bring the already established Australian Infant formula into millions of American homes. The Food and Drug Administration the U.S., certifying that the Australian-made Care A2+ Infant Formula meets the standards set by the FDA. In early January 2023 the FDA extended the

Arcturus Therapeutics Holdings Inc. a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Clinical Trial Application (CTA) for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis (CF), received approval to proceed into a Phase 1 First-in-Human study in New Zealand. “Arcturus continues to progres

Zhongchao Inc.a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that that Chongqing Xinjiang Pharmaceutical Co., Ltd.one of the China operating entities, of which the Company consolidates the financial results with through certain contractual arrangements, obtained the general distribution rights in Mainland China for anti-influenza drug from Natco Pharma Limited ("Natco"). Natco is a vertically integra

Virpax Pharmaceuticals, Inc.a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, and central nervous system disorders, today announced that the Company has engaged New England Investors, LLC to serve as the out-licensing advisor for Envelta in the People’s Republic of China. Envelta is Virpax’s non-opioid pain product candidate for acute and chronic pain including non-cancer pain. “We have engaged New Engl